Our position in American pharmaceutical company, Eli Lilly & Company (1.8%), was a top contributor to relative returns during the fourth quarter.

These two stocks could be poised for a bounce back. The post Should you buy low on these ASX healthcare stocks? appeared first on The Motley Fool Australia.

Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.